Navigation Links
New Latent TB Drug Saves Lives, Money
Date:5/20/2008

Rifampin improved compliance, reduced side effects, saved $10,000 per patient

TUESDAY, May 20 (HealthDay News) -- Using the drug Rifampin to treat people with latent tuberculosis saves time, money and lives, new research shows.

"We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the health-care system," lead analyst Anne Aspler, of the respiratory epidemiology and clinical research unit at McGill University's Montreal Chest Clinic, said in a prepared statement.

"Overall, Rifampin costs about $484 less per patient treated, which, if we assume that four months of Rifampin has a least equal efficacy to nine months of Isoniazid, represents an added savings to the health system of more than $10,000 per patient prevented from developing [full-blown] TB disease. And because of improvements in compliance, we are actually preventing more cases. This treatment can save money as well as lives," Aspler said.

The study was expected to be presented Tuesday at the American Thoracic Society's International Conference, in Toronto.

Currently, about 2 billion people worldwide are believed to have latent, or dormant, TB. Of those, 8 million to 9 million will develop TB each year, and 1.6 million of them will die.

TB is most prevalent in developing countries, where Rifampin is offered at a subsidized cost through the Global Drug Facility of the World Health Organization. Not only is Rifampin less expensive, it has better patient compliance than Isoniazid due to the shorter treatment time, according to Aspler.

"While Isoniazid therapy is 90 percent effective for those who complete it, in reality, fewer than 50 percent do," Aspler said. This low compliance rate can have serious health consequences for patients who fail to complete treatment and for those they later infect.

Previous research and experience suggests that a four-month treatment program improves patient compliance by 20 percent to 25 percent, and reduces the risk of serious side effects such as liver damage.

"The next step in research is a major phase III clinical trial of efficacy -- ideally in HIV-infected and non-infected patients and in low-income settings where tuberculosis is the leading cause of death in people living with HIV," Aspler said.

More information

The National Institute of Allergy and Infectious Diseases has more about TB.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, May 20, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New chemical can kill latent tuberculosis bacteria
2. Rifampin: Latent TB treatment saves time money and lives
3. Surgery for severe obesity saves lives
4. Early Breast Cancer Detection Saves Lives
5. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
6. iPlan(R) Automatic Segmentation Saves 25 Minutes of Treatment Planning Time for Each Prostate Cancer Patient at the University of Nebraska Medical Center
7. Fetal Surgery Saves Baby After Early Water Break
8. Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions
9. Wal-Mart Saves Customers More Than $1 Billion On Prescription Drugs
10. Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act
11. American College of Medical Genetics Commends the Signing of the Newborn Screening Saves Lives Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... through the Pennsylvania Cable Network (PCN) during the summer of 2016. The program ... Grant provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that due ... Texas, they are expanding their presence in Dallas. One of the most exciting parts ... new jobs to the Dallas and Forth Worth market. STAT takes pride in treating ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016  RxWiki Inc., a digital health company ... strategies of thousands of pharmacies through its Digital Pharmacist ... Inno,s "50 on Fire" Award in the Health ... to accept the award as one of Austin,s fastest ... Officer at RxWiki. "Our platform gives independent retail pharmacies ...
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology: